The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
=== Caged and cage-free eggs === On November 5, 2015, Panera pledged that it would use only cage-free eggs in all of its stores by 2020. Panera also announced the addition of more plant-based proteins, such as edamame and organic quinoa, to its menu. At the time of the announcement, the company said it was 21% cage-free in the roughly 70 million eggs it used in 2015. In December 2016, it published its third animal welfare progress report, announcing new efforts to improve broiler chicken welfare. In 2021, Panera announced that it had transitioned to cage-free eggs for 65% of its egg supply but not yet the remaining 35%.
== Pharmacology == It is a derivative of isonipecotic acid, like pethidine, and is metabolized in part to norpethidine. Its potency range is due to method of ingestion. figure 20–80 times as potent as pethidine as an analgesic. The greatly increased potency essentially eliminates the toxic effects of norpethidine accumulation which are seen when pethidine is administered in high doses or for long periods of time.
That [RnO3F]− did not form in other experiments may have been due to the high concentration of fluoride used. Electromigration studies also suggest the presence of cationic [HRnO3]+ and anionic [HRnO4]− forms of radon in weakly acidic aqueous solution (pH > 5), the procedure having previously been validated by examination of the homologous xenon trioxide. The decay technique has also been used. Avrorin et al. reported in 1982 that 212Fr compounds cocrystallised with their caesium analogues appeared to retain chemically bound radon after electron capture; analogies with xenon suggested the formation of RnO3, but this could not be confirmed. It is likely that the difficulty in identifying higher fluorides of radon stems from radon being kinetically hindered from being oxidised beyond the divalent state because of the strong ionicity of radon difluoride (RnF2) and the high positive charge on radon in RnF+; spatial separation of RnF2 molecules may be necessary to clearly identify higher fluorides of radon, of which RnF4 is expected to be more stable than RnF6 due to spin–orbit splitting of the 6p shell of radon (RnIV would have a closed-shell 6s26p21/2 configuration). Therefore, while RnF4 should have a similar stability to xenon tetrafluoride (XeF4), RnF6 would likely be much less stable than xenon hexafluoride (XeF6): radon hexafluoride would also probably be a regular octahedral molecule, unlike the distorted octahedral structure of XeF6, because of the inert pair effect.
Erythroferrone is a protein hormone encoded in humans by the ERFE gene. Erythroferrone is produced by erythroblasts, inhibits the production of hepcidin in the liver, and so increases the amount of iron available for hemoglobin synthesis. Skeletal muscle secreted ERFE has been shown to maintain systemic metabolic homeostasis.
Sources: en.wikipedia.org
== Lifecycle == Bowfin spawn in the spring or early summer, typically between April and June, more commonly at night in abundantly vegetated, clear, shallow water in weed beds over sand bars and also under stumps, logs, and bushes. Optimum temperatures for nesting and spawning range between 16 and 19 °C (61 and 66 °F). The males construct circular nests in fibrous root mats, clearing away leaves and stems. Depending on the density of surrounding vegetation, a tunnel-like entrance may be at one side. The diameter of the nests commonly range between 39 and 91 cm (15 and 36 in), at a water depth of 61–92 cm (24–36 in). During spawning season, the fins and underside of male bowfin often change in color to a bright lime green. The courtship/spawning sequence lasts 1-3 hours and can repeat up to five times. Courtship begins when a female approaches the nest. The ritual consists of intermittent nose bites, nudges, and chasing behavior by the male until the female becomes receptive, when the pair lie side by side in the nest. She deposits her eggs, while he shakes his fins in a vibratory movement, and releases his milt for fertilization to occur. A male often has eggs from more than one female in his nest, and a single female often spawns in several nests. Females vacate the nest after spawning, leaving the male behind to protect the eggs during the 8-10 days of incubation. A nest may contain 2,000 to 5,000 eggs, possibly more. Fecundity is usually related to size of the fish, so the roe of a large gravid female may contain over 55,000 eggs.
Historians have explored how the Napoleonic wars became total wars. Most historians argue that the escalation in size and scope came from two sources. First was the ideological clash between revolutionary/egalitarian and conservative/hierarchical belief systems. Second was the emergence of nationalism in France, Germany, Spain, and elsewhere, that made these "people's wars" instead of contests between monarchs. Bell has argued that even more important than ideology and nationalism were the intellectual transformations in the culture of war that came about through the Age of Enlightenment. One factor, he says, is that war was no longer a routine event but a transforming experience for societies—a total experience. Secondly, the military emerged in its own right as a separate sphere of society distinct from the ordinary civilian world. The French Revolution made every civilian a part of the war machine, either as a soldier through universal conscription, or as a vital cog in the home front machinery supporting and supplying the army. Out of that, says Bell, came "militarism", the belief that the military role was morally superior to the civilian role in times of great national crisis. The fighting army represented the essence of the nation's soul. As Napoleon proclaimed, "It is the soldier who founds a Republic and it is the soldier who maintains it." Napoleon said on his career "I closed the gulf of anarchy and brought order out of chaos. I rewarded merit regardless of birth or wealth, wherever I found it.
=== Inequalities === People living with AD and other forms of dementia and their unpaid carers might face inequalities in access to and the quality of care and support services. These inequalities can depend on various factors, including socio-economic background, housing situation, education level, gender, and race. People might have differences in how easily they can access AD services based on where they live. On a global level, people in low-and middle-income countries have fewer available facilities and services, and have greater difficulties accessing these than people living in high-income countries. As a result of AD and other forms of dementia being less recognised and treated in the healthcare systems of these countries, the level of awareness of AD as something caused by disease is relatively lower. At the same time, the local socio-cultural understandings of aging, senility, and eldercare may have larger effects on care provision and the reception of medical services. On a national level, people with AD might have unequal access to care based on where they live. This can manifest on a regional level, with people in rural areas facing more difficulties than those in urban areas. Inequalities can also affect smaller local units as well, for example people living in the same city might receive different or less frequent care based on their postcodes or the street they live in. Inequalities also affect people with AD from ethnic minority groups.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.